GlassScriptPhysician profile
Rachel Main
NPI 1346869674
$1,646.47
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $577 · 2023: $441 · 2024: $24.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $493.38 | 2021-2023 | Belbuca, Xtampza |
| Abbvie INC. | $169.46 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.16 | 2021-2023 | Relistor |
| Novo Nordisk INC | $134.69 | 2021-2023 | Wegovy |
| Boston Scientific Corporation | $111.42 | 2021 | |
| Ibsa Pharma INC. | $102.56 | 2021-2023 | Tirosint, Licart |
| Almatica Pharma LLC | $98.66 | 2021-2022 | |
| Amgen INC. | $74.82 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $67.91 | 2023 | Xeomin |
| Arbor Pharmaceuticals, INC. | $50.12 | 2021-2022 | |
| Fidia Pharma USA INC. | $48.91 | 2021-2024 | Hyalgan, Hymovis, Triluron |
| Biohaven Pharmaceutical Holding Company LTD. | $34.11 | 2022 | |
| Azurity Pharmaceuticals, INC. | $33.64 | 2023 | Horizant |
| Si-Bone, INC. | $26.97 | 2021 | |
| Lilly USA, LLC | $24.24 | 2021-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $18.57 | 2023 | Physio-Stim |
| Hikma Pharmaceuticals USA | $15.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Main listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.